2026 SITC Biotech Strategic Meeting at the NYSE

Friday, June 26 at the New York Stock Exchange (Sold Out)

Join investors and leaders from biotechnology, biopharma, academia, and regulatory agencies for high-level strategic dialogue on the future of cancer immunotherapy.

Join the waitlist for future events

Images courtesy of NYSE Group. NYSE does not recommend or endorse any investments, investment strategies, companies, products or services.

The 2026 SITC Biotech Strategic Meeting at the New York Stock Exchange is supported, in part, by: BioNTech US Inc, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, and SITC Biotech Community Members, Astellas, BioCytics and Carolina BioOncology Institute, Dana-Farber Cancer Institute, Genentech, Lumanity, Lytix Biopharma, Miltenyi Biotec B.V. & Co. KG, Molecular Partners, Numenos, Precision for Medicine, Replimune Inc., Xilio Therapeutics (supporters as of June 25, 2026).

Gold Supporter

BioNTech US Inc

Gold Supporter

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc

Biotech Community Member

Astellas

Biotech Community Member

BioCytics Inc and Carolina BioOncology Institute

Biotech Community Member

Dana-Farber Cancer Institute

Biotech Community Member

Genentech

Biotech Community Member

Lumanity

Biotech Community Member

Lytix Biopharma

Biotech Community Member

Miltenyi Biotec B.V. & Co. KG

Biotech Community Member

Molecular Partners

Biotech Community Member

Numenos

Biotech Community Member

Precision for Medicine

Biotech Community Member

Replimune Inc.

Biotech Community Member

Xilio Therapeutics

Thank you to our program organizers.

David Kaufman, MD, PhD
Program Co-Chair
David Kaufman, MD, PhD
Third Rock Ventures
Holger Kissel, PhD
Program Co-Chair
Holger Kissel, PhD
Claudia-Nanette Gann, MD
Claudia-Nanette Gann, MD
BioNTech SE
Jarrett Rieger, Esq
Jarrett Rieger, Esq
Moffitt Cancer Center
Alexandra Snyder, MD
SITC Biotech Committee Co-Chair
Alexandra Snyder, MD
Merck
Zhen Su, MD, MBA
Program Co-Chair
Zhen Su, MD, MBA
Marengo Therapeutics
Kasia Urbanska, PhD
Kasia Urbanska, PhD
Bristol Myers Squibb

Program Description

The annual biotech strategic meeting at the NYSE convenes a highly curated group of biotech executives, investors and drug development leaders to explore the most pressing strategic questions shaping the future of immuno-oncology.

The program will feature discussions on late-stage and commercial biotech strategy, emerging modalities such as in vivo cell therapies, AI-enabled drug development and the evolving global regulatory and financing landscape.

Designed to foster meaningful dialogue and high-value connections, this forum offers a unique opportunity to engage directly with leaders driving innovation and deal making across the biotech ecosystem.

The 2026 Event is Sold Out. Join the
Waitlist for Future Biotech Meetings!

Program Schedule

2026 SITC Biotech Strategic Meeting at the NYSE

Friday, June 26, 2026 · New York Stock Exchange

Time Session
8:00 – 8:45 AM ET
Arrivals and Breakfast
8:45 – 9:15 AM ET
Welcome & Bell Ringing Ceremony Kickoff
Speakers:
  • Johanna Grossman, PhD - New York Stock Exchange
  • James Gulley, MD, PhD, FACP - National Cancer Institute (NCI)
  • Zhen Su, MD, MBA - Marengo Therapeutics
9:15 – 9:45 AM ET
Tour of the NYSE Floor & Bell Ringing
9:45 – 10:05 AM ET
Commercializing IO Biotechs
Summary of the collaborative programming with ZS on Thursday, June 25th
Speaker:
  • Jeffrey Aroy, MBA - ZS
  • Cody Powers, MBA - ZS
10:05 – 10:25 AM ET
Keynote Presentation: Trends and Data in the IPO Market
Speaker:
  • Daina Graybosch, PhD - Leerink Partners
10:25 – 10:45 AM ET
Keynote Presentation: IO Dealmaking and Partnership Trends
Financing, investing, dealmaking of biotech innovation in immuno-oncology
Speaker:
  • Andrew Baum, MD - Pfizer
10:45 – 11:05 AM ET
Keynote Q&A
11:05 – 11:10 AM ET
Break
11:10 – 11:50 AM ET
Considerations of Launching a New Company
Moderator: David Kaufman, MD, PhD - Third Rock Ventures
Speakers:
  • Lex Johnson, PhD - Dispatch Bio
  • Beverly Lu, PhD - Yosemite
  • John Swartley, PhD - Penn Center for Innovation
  • Michael Rosenzweig, PhD - Abbvie
  • Chris Wilfong, MBA - Two River
11:55 – 12:35 PM ET
Liquidity in Biotechs, Mergers and Acquisitions
How companies navigate strategic choices in public markets
Moderator: Ken Song, MD - Candid Therapeutics
Speakers:
  • Christopher Heery, MD - Arcellx
  • Kristen Hege, MD - Board Member: Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune
  • Mary Jane Hinirchs, PhD - Ipsen
  • Paul Peter Tak, MD, PhD, FMedSci - Candel Therapeutics
12:35 – 1:30 PM ET
Lunch
1:30 – 2:10 PM ET
China's Strategy for Western IO Biotech
Insight into IST pathways and operational innovation
Moderator: Lei Lei Wu - Endpoints News
Speakers:
  • Claudia-Nanette Gann, MD - BioNTech
  • David Kolesky, PhD - MPM
  • Ji Li, PhD
  • Leon 'Jun' Tang, PhD - InScienceWeTrust BioAdvisory
2:15 – 2:55 PM ET
Developing AI Assisted Computational Therapies
The state of AI investments through clinical and developmental landscapes
Moderator: Alexandra Snyder, MD - Merck
Speakers:
  • Dinesh de Alwis, PhD - Generate Biomedicines
  • John E. Connolly, PhD - Parker Institute for Cancer Immunotherapy
  • Vicki Goodman, MD - Recursion
3:00 – 3:40 PM ET
What's Coming Next and Disrupting the Future of the Field
From novel engineering to unlocking the TME
Moderator: Kasia Urbanska, PhD - BMS
Speakers:
  • Uli Bialucha, PhD - Xilio Therapeutics
  • Jenny Hamilton, PhD - Azalea Therapeutics
  • Michael Rosenzweig, PhD - Abbvie
  • Dimitris Skokos, PhD, MBA, MS - Regeneron
3:40 – 3:45 PM ET
Closing Remarks and Synthesis
Zhen Su, MD, MBA - Marengo Therapeutics

ZS and SITC Biotech Panel and Networking Event

ZS and the Society for Immunotherapy of Cancer (SITC) are excited to partner for a second year to host The Last Mile of Developing Next Wave IO—an exclusive evening bringing together biotech leaders navigating the path to launch. This invite-only program features a panel exploring the realities of advancing next-generation therapies in their final stages, alongside brief presentations on emerging market trends and an analysis of first launches. Join us the night before the NYSE program for meaningful conversation, networking and standout views of the Empire State Building.

Registration Rates

In-Person Registration Rates

Early Rate
Ends May 18		 Regular Rate
Industry Member $400.00 $450.00
Industry Non-Member $800.00 $850.00
Member $200.00 $250.00
Non-Member $400.00 $450.00
Student Member $50.00 $100.00
Student Non-Member $100.00 $150.00

What you missed last year.

Innovation doesn't wait. Don't miss groundbreaking, cross-sector meetings with leaders across biotech, finance and regulatory agencies.